Replies to post #242698 on Biotech Values

[DewDiligence]

Sarissa’s new 13D filing is essentially an addendum to 13D filed in Jan 2022 (https://www.sec.gov/Archives/edgar/data/0000897448/000089914022000088/s49762134a.htm ); the intention of seeking BoD representation is the main difference.

[jbog]

I've done very well following Denner


Sales:

Imclone
Medicines Company
Ariad Pharma

He also forced the spinoff of Bioverativ from Biogen which Sanofi snapped up.